The four adenosine receptors, A1, A2A, A2B and A3, constitute a subfamily of G protein-coupled receptors (GPCRs) with exceptional foundations for structure-based ligand design. The vast amount of mutagenesis data, accumulated in the literature since the 1990s, has been recently supplemented with structural information, currently consisting of several inactive and active structures of the A2A and inactive conformations of the A1 adenosine receptor. We provide the first integrated view of the pharmacological, biochemical and structural data available for this receptor family, by mapping onto the relevant crystal structures all site-directed mutagenesis data, curated and deposited at the GPCR database (available through http://www.gpcrdb.org).
or the mutagenesis/modeling combination known as biophysical mapping (BPM) [22] , a technique recently employed to design A2AAR antagonists [23] . These different sources of experimental data can be integrated in computational models, which are used to elucidate the molecular determinants of ligand binding and receptor function [24] . In the ARs, protocols like proteochemometrics (PCM) [25] or free energy perturbation (FEP) [24, 26] have successfully filled the gap between affinity and structural data (Box 1).
We herein review all the available mutagenesis data on the light of the structural information available for ARs. To do so, the existing SDM data was systematically collected from 80 individual publications and the resulting 2624 curated data points, of which 96% are from human receptors, were made available through the GPCRdb [27] . A comprehensive mapping of these data onto the available structural information provides an overview of ligand binding and activation events, which we present here in three sections: 1) Orthosteric ligand binding, 2) Allosteric modulation and 3) Receptor activation and G protein binding (Figure 1, Key Figure) .
Orthosteric ligand binding
The common core scaffold of agonists and antagonists Classical AR agonists and antagonists share a number of interactions within the orthosteric binding pocket, since they are derived of a similar planar heterocycle (Box 2), from where modifications can confer high affinity, selectivity and/or intrinsic activity (i.e. the ribose moiety).
The crystal structures of the A2AAR confirmed that the central heterocycle of both agonists and antagonists resides in the same binding pocket, dominated by hydrogen bonds (H-bonds) with the completely conserved N253 6x55 (N/N/N/N) in all AR subtypes (see Box 3 for an explanation on residue numbering). The key role of this residue was suggested by early alanine scannings in different ARs, [22, [28] [29] [30] [31] [32] in all cases abolishing ligand binding ( Figure 2b ) while retaining normal expression and basal activity levels [28] . The heterocyclic core is further stabilized by stacking with F168 45x52 (F/F/F/F) in the second extracellular loop (EL2), which could be replaced by another aromatic residue (tryptophan) with no significant changes in ligand binding affinities [28, 33] . The neighboring residue, E169 EL2 (E/E/E/V), is involved in ligand binding, through an H-bond in the scaffolds bearing an exocyclic amino group (Figure 2a and Box 2), while it can create a lid closing the binding site via a salt bridge interaction with H264 EL3 (H/H/N/-) [34] . This double role explains why mutation to alanine completely abolishes binding of the agonist CGS21680 [35] and the antagonist ZM241385 [36] , while binding is preserved upon a more conservative mutation to glutamine. Interestingly, the A2AAR has been crystallized with and without this salt bridge linking EL2 and EL3, and in the A1AR K265 EL3 (K/A/G/P), might replace H264 EL3 in this salt bridge. The role of this salt bridge in ligand binding kinetics is explained below.
Selectivity hotspots: mutagenesis suggestions confirmed by crystal structures
Deeper in the binding pocket, H250 6x52 (H/H/H/S) stabilizes both agonists and antagonists, through interaction with the different modifications emerging from the core scaffold. This is in line with the abolished A2AAR binding observed in the H250 6x52 A mutant [30, 32] , while mutation to a bulky phenylalanine did not significantly affect antagonist binding ( Figure 2b ) [32, 37] . The A3AR has a serine in this position, which might explain why it is more tolerant towards larger substituents binding deep in the pocket. Another selectivity hotspot was recently 6 confirmed for the A1AR, where T270 7x34 (T/M/M/L), a previously proposed hotspot for A1AR interspecies selectivity [38] , accommodates cycloalkylic groups at the C8-position of xanthines, characteristic of A1-selective xanthine derivatives ( Figure 2c ) [14, 15] . Consequently, a M270T 7x34 mutant A2AAR showed increased affinity for A1 selective ligands, whose affinity was correspondingly reduced in the inverse mutant (T270M 7x34 mutant of the A1AR [14, 15] ). The comparison of A1AR and A2AAR inactive structures highlighted another difference leading to antagonist selectivity. The N1-substituent of the xanthine derivative PSB-36 occupies a narrow cavity between TM3, TM5 and TM6 in the A1AR, which is not present in the A2AAR.
Consequently, PSB-36 is forced to sit in an alternative, less-favorable position [15] .
Triggering receptor activation: residues involved in agonist recognition
The triad formed by E13 1x39 (E/E/E/E) -S277 7x42 (T/S/S/S) -H278 7x43 (H/H/H/H), together with T88 3x36 (T/T/T/T) and H250 6x52 (H/H/H/S), constitute the main binding site for the ribose moiety in (full) agonists ( Figure 2d ). This triad was proposed in the early nineties as an important structural feature for AR activation [39] , further supported by experiments using a 'neoceptor' approach [40, 41] (Box 3). The E13 1x39 -H278 7x43 interaction is present in all agonist crystal structures, stabilizing the conformation of H278 7x43 required to form an H-bond with the ribose moiety. Consequently, mutations of E13A 1x39 reduce the potency of full agonists, but interestingly not of non-nucleoside partial agonists [28] . Using molecular dynamics (MD) simulations, Rodríguez et al. showed that this interaction was not only less stable in the absence of a ligand, but also dependent on the protonation state of the residues involved, which might be altered by the presence of full agonists [42] . Removal of either of the two histidine sidechains in the binding site in the H250A 6x52 [30, 32] and H278A 7x43 [32] mutants strongly decreased agonist potency and binding, and also reduced antagonist binding.
Mutation of other polar sidechains coordinating the ribose in the A2AAR (S277A 7x42 [32] and T88A 3.36 [43] ) reduced agonist potency, but increased antagonist binding and the potency of the partial agonist LUF5834 [28] . Crystal structures of agonist-bound A2AAR show a direct interaction between NECA and T88 3x36 through the amide in position 5' of the ribose, which is not present in adenosine. This could explain why NECA is more sensitive to the T88A 3.36 mutation and has a higher affinity than adenosine for the A2AAR [43] [44] [45] . Mutations of the polar sidechain at position 7x42 have a drastic effect on agonist binding, as seen in alanine mutants in the A2BAR (S279A 7x42 ) [46] and the A1AR (T277A 7x42 ) [47] [48] [49] . Additionally, the inactive A2A StaR ('stabilized receptors'; Box 1) contains alanine mutations of T88 3.36 and S277 7x42 [50] , while antagonists crystalized with the wild-type (wt) receptor do not show interactions with these residues, all of which points to a role of these polar sidechains in attaining a fully active conformation. Interestingly, the same mutants have negligible or even positive effects on the potency and/or efficacy of partial agonists at the A1 [47] [48] [49] and A2A ARs [28] .
Mutations on the orthosteric site, which represent 80% of the collected mutational data on ARs, have been characterized in more detail than the mutations on the allosteric or G protein sites described in the next sections. Indeed, In silico site-directed mutagenesis simulations of several A2AAR orthosteric-site mutants (Box 1) provided a nice complement to the structural analysis of static crystal structures discussed above, revealing non-evident effects like water-mediated interactions or the role of mutations which are not in direct contact with the ligand [24, 26] . 8 
The extracellular region: Ligand kinetics and receptor architecture
Mutations in the ELs do not only influence binding of orthosteric ligands, but may also play a role in ligand kinetics. In addition, this region plays a structural role through a series of cysteine bridges, and has been related to selectivity among certain receptor subtypes. Finally, mutational studies and lately crystal structures [11] suggest that this region might be the binding site of allosteric modulators, in analogy to other GPCRs [51] . Here we will discuss the mutational data of the EL region in ARs.
Residues that govern the kinetics of ligand binding
Ligand binding kinetics governs the residence time of a drug, which has deep implications on its clinical efficacy [52] . The kinetics of ligand binding in adenosine receptors has been demonstrated to be extremely variable, as recently examined by SDM and other methods [53] .
Residues distant from the orthosteric site can influence the kinetics of ligand binding without altering the binding affinity constant (Ki). For instance, the kon and koff values ZM241385 on StaR versus wt receptors are significantly slower, but the binding affinity remains unaltered [54] . and L267A 7x31 (S/L/K/Q)] the koff of ZM241385 [36] , while its affinity was minimally affected. 9 This led to the conclusion that these residues should play a role in the dissociation pathway of ZM241385. Recent mutagenesis, crystal structures and MD simulations confirmed that breaking the salt bridge between E169 EL2 , H264 EL3 (supported by polar interactions with T256 6x58 ) is crucial in the dissociation of ZM241385 [36, 55] , as previously indicated by MD simulations of A2A and A2B receptors [42] . The stabilization of the salt bridge between E169 EL2 and the positively charged H264 EL3 should be considered in the design of A2AR antagonists with long residence time.
Architecture and stability of the variable EL2 region
The extracellular region -especially EL2 -differs within the AR family in terms of sequence length, composition and even tertiary structure ( Figure 3b ) [14, 15] . The existence of cysteine bridges, which play an important role in the architecture and stability of the EL2, is variable between ARs. The cysteine bridge formed between C77 3x25 (C/C/C/C) -C166 45x50 (C/C/C/C) is a highly conserved motif in class A GPCRs (87%) shared amongst all ARs [27] (Figure 3b ). Serine mutations of one of these cysteines abolished ligand binding in the A1 [56] and A2B ARs [57] , but in the A2AAR only resulted in reduced potency or affinity of small agonists (e.g. NECA, adenosine), whilst having no effect on larger 2-substituted adenosine derivatives (e.g. CGS21680) [51] . The reduced effect on this receptor could be understood with the first A2AAR crystal structures, revealing additional disulfide bridges that reinforce the architecture of EL2 due to two extra cysteines in this loop. Serine mutations of these cysteine residues [C146 EL2 (L/C/K/K) and C159 EL2 (M/C/G/S)] resulted in a lower potency of adenosine, but did not alter the potency of NECA and CGS21680. On the contrary, serine mutations in the A2BAR of the three cysteine residues present in EL2 [C154 EL2 (W/K/C/R), C166 EL2 (K/A/C/-), C167 EL2 (-/-/C/-)] did not affect ligand binding, indicating that they are not involved in disulfide bond formation [57] . Finally, the dynamics of the EL region might play a role in the allosteric modulation of ARs, which we will explain in the next section.
Sites for allosteric modulation in ARs
Allosteric modulation of GPCRs is gaining acceptance as a new approach for drug development, since allosteric ligands typically display higher target selectivity compared to orthosteric ligands [3, 58] . In ARs, two distinct receptor regions have been revealed as sites for allosteric modulation ( Figure 3 ): the EL2 region and the sodium binding pocket.
The EL2 as an allosteric region
The role of the extracellular loops in receptor structure and dynamics might explain why this region has been identified as a site for the binding of both positive (PAM) and negative (NAM) allosteric modulators. The A2A-selective agonist CGS21680, as well as other non-selective agonists, showed an increased efficacy in a chimeric A2BAR receptor containing the EL2 of the A2AAR in comparison to the wt A2BAR [59, 60] . These results suggest an allosteric control of EL2, since the increased agonist efficacies can be explained by the role of this loop in stabilizing agonist-bound receptor conformations [59] . Moreover, ligand selectivity may be achievedprobably by an indirect effect -in extracellular regions far away from the ligand binding pocket [61] [62] [63] . Recent results on the A1AR provide additional evidence to the idea that ARs can be activated by positive allosteric modulators binding to the EL regions [64, 65] . These insights have been recently complemented by the observation of a potential allosteric pocket in a recently published antagonist-bound A2AAR structure [13] .
Allosteric modulation by sodium ions and amilorides
Sodium ions down-regulate the pharmacological response of GPCRs, including the A2AAR [66] . Figure 3d ) [12] . This finding was followed by SDM and biophysical characterization of this pocket, combined with MD simulations, which revealed a mechanism of allosteric control where sodium specifically stabilizes the inactive conformation of the receptor [67, 68] . Upon agonist binding, the sodium binding site collapses due to a concerted movement of several residues situated in TM3, TM6 and TM7. In particular, an H-bond is formed between the backbone oxygen in N284 7x49 , part of the highly conserved NPxxY motif, and D52 2x50 , which is one of the highest conserved residues amongst the entire family of GPCRs [27, 69] . Accordingly, alanine mutations of both N284 7x49 [67, 70] and D52 2x50 [67, 71] had little effect on antagonist or agonist binding but completely abolished receptor activation. A series of MD simulations of the 2-adrenergic receptor, mapped onto the A2AAR crystal structures, concluded that the protonation state of D52 2x50 changes during the activation pathway from an inactive, deprotonated, to an active, protonated state. In this scenario, S91 3x39 would play a regulatory role in the protonation of D52 2x50 , as mutations to alanine in A1 and A2A
ARs increase their basal activities [44, 67, 69] . In the active-like state, the backbone interaction between D52 2x50 and N284 7x49 causes a helix bulge in TM7, leading to conformational rearrangements related to receptor activation as discussed in the next section.
Another conformational change is initiated by the movement of residues W246 6x48 and F242 6x44 , which propagates to an outward shift of TM6 as observed in agonist-bound and fully activated structures ( Figure 3c ). This movement might be blocked by amiloride and derivatives, which are NAMs predicted to bind to the sodium site [67] , which is in line with data showing that F242A 6x44 mutations increase the thermostability of agonist-bound A2AAR [50] . Tryptophan W246 6x48 , previously coined as the 'toggle switch' [9] , forms a bulky lining separating the orthosteric site from the sodium binding site. Mutation to alanine did not alter agonist binding to the A3AR, but receptor function was completely lost [30, 71, 72] . Similarly, on the A2AAR the corresponding W246 6x48 A mutant reduced the efficacy of full agonists, whereas the activity of partial agonists was slightly increased [28, 46, 67, 73] .
Mutations in the sodium pocket affect amilorides in a different way compared to sodium.
Allosteric modulation by sodium was completely abolished in D52A 2x50 and N284A 7x49 receptor mutants, but the latter showed increased affinity for amilorides. The interpretation, supported by MD simulations, was that the positively charged guanidinium group of amiloride would form a salt bridge with D52 2x50 , while N284 7x49 , N280 7x45 , and W246 6x48 would make suboptimal interactions with amilorides. Additionally, W246A 6x48 has been shown to increase the competitive behavior of amilorides in radioligand binding assays with ZM241385, due to an increased penetration of 5'-substituted amilorides into the orthosteric binding site in the mutant receptor [74] . 13 
Receptor signaling and G protein binding
The intracellular side of the TM bundle is more conserved within the GPCR superfamily than the extracellular domain [2] . This region undergoes the most pronounced conformational changes upon receptor activation and is implicated in the binding of the intracellular G-protein. Four motifs play a major role here ( Figure 4) : NPxxY in TM7, the DRY motif (TM3), the ionic lock and the TDY triad, as observed in the G protein-bound crystal structure [19] .
The TM7 NPxxY motif
This motif is located in TM7 and contains N284 7x49 , which has been discussed above as part of the sodium binding site, and is the center of the helix bulge observed in A2AAR active-like structures (Figure 3d ). Residue Y288 7x53 experiences an upward movement and undergoes an Hbond interaction with Y197 5x58 (Y/Y/Y/Y) in the G protein-bound structure (Figure 4b ). These pair of tyrosines is considered as a possible activation switch, based on their high conservation in class A GPCRs [27] and their specific interaction in the G protein-bound state, while the sidechain of Y197 5x58 was shown to flip out into the membrane in A2AAR agonist-bound crystal structures [16] [17] [18] (Figure 4b ). The Y282F 7x53 mutation in the A3AR resulted in a nearly 30-fold reduction in potency for Cl-IB-MECA, but did not alter basal activities [75] . In the A2BAR, the Y197S/N 5x58 mutations, which maintain the polarity of the wt tyrosine, led to an increase in constitutive activity [62] . To fully understand the role of the Y197 5x58 -Y288 7x53 switch in AR activation, mutations to alanine and phenylalanine would be of particular interest. 14 
The TM3 DRY motif
The GPCR conserved DRY (D101 3.49 
motif in TM3 binds the C-terminus of the G protein in the fully activated A2AAR. R102A 3.50 moves towards Y197 5x58 , in analogy to the fully-active β2 structure, to allow the G protein to move in, and undergoes intensive van der Waals interactions with Y391 in the mini Gs-A2AAR bound structure [19] . In a mutational study on the A2BAR addressed to investigate its selectivity for G proteins, it was found that R102A 3.50 maintained potency and maximum response close to the wt receptor for the Gαs subtype, but lost potency for seven other subtypes [76] . In the A3AR, mutations R102A 3.50 and R102K 3.50 led to constitutively active receptors [75] . Interestingly, two structural motifs, the ionic lock ( Figure 4c ) and the TDY triad (Figure 4d ), keep R102 3.50 locked in the conformation observed in inactive and agonist-bound structures of A2AAR, as opposed to the corresponding fully-active, mini Gs-A2AAR crystal structure.
The ionic lock
The salt bridge formed between E228 6x30 (E/E/E/E) and R102 3x50 (R/R/R/R), also called the ionic lock, is proposed to be an important factor in the deactivation of the receptor. It is present in several but not all A2AAR inactive crystal structures [10] . No mutation data is available for residue E228 6x30 in ARs, but other experimental work points towards a regulatory role of this salt-bridge in receptor activation. In particular, NMR based studies of the A2AAR show a rapid interchange (low millisecond timescale) of two antagonist states, associated with ionic lock formation [20] . In analogy to the case of the 2 adrenergic receptor, MD simulations of the A2AAR, starting from a conformation where the ionic lock was not present, showed a rapid formation (10 -15 ns timescale) and highly stable (100ns) ionic lock interaction [42, 77] . A recent A2AAR crystal structure revealed an interaction between E228 6x30 and R107 3x55 (K/R/C/K) [13] , which together with the thermostabilizing effect of the R107A 3x55 mutant [10] , suggests a role of this residue against the formation of the ionic lock.
The TDY triad
fully conserved amongst all AR subtypes and some other class A families (e.g. β-adrenergic and dopamine receptors) [27] . This triad has previously been suggested to be involved in a network of polar interactions stabilizing the ionic lock [42] . The T41 2x39 A mutation has been shown to produce constitutively active A2BARs [29, 78] . In the A3AR, mutations of D107 3x49 to asparagine, lysine and arginine did not significantly alter the basal activities of the receptor or the potency of agonists [75] . No mutational data for Y112 34x53 is available for ARs. Notably, the structural differences of the corresponding TDY triad in the different conformations of the β2 adrenergic receptor are more pronounced than in the A2AAR. In all β2 structures the IL2 is disordered except for the fully activated structure, where the region forms an-alpha helix. This results in a H-bond between Y 34x53 and D 3x49 , possibly altering the salt bridge strength between R 3x50 and D 3x49 . In the A2AAR, the IL2 is consistently found in an alpha helical conformation, and the shape of the TDY triad remains the same. Additional mutagenesis experiments are needed to confirm a possible regulatory role of this triad in the activation of ARs and other class A GPCRs.
Concluding Remarks
The effects of point mutations of the four ARs on ligand binding affinities, functional potencies and efficacies constitute a valuable source of pharmacological information. We analyzed the existing data and mapped it on the collection of available AR crystal structures, allowing for a comprehension of receptor-ligand interactions and receptor activation outstanding within the GPCR families. A majority of the mutational data collected refers to orthosteric ligand binding, where combinations of SDM and crystal structures led to the design of AR antagonists [79] , and novel computational protocols have provided with detailed energetic descriptions of ligand binding. Still, some issues remain unsolved with regard to ligand optimization, such as achieving better selectivity ratios or attaining an agonist functional response on ligands lacking a ribose moiety, though recent advances in this regard are promising [80] . Allosteric modulation is a promising pharmacological strategy to overcome some of these issues, but while there is indirect evidence pointing to the location of allosteric sites on the EL region, a crystal structure with an allosteric modulator is still lacking. The kinetic characterization of ligand binding is an emerging area, though not yet fully understood, where new mutational and structural data could be particularly helpful. Finally, the crystal structures of A2AAR provide a complete landscape of end-point receptor conformational states, complemented with mutational data that points to specific activation switches, but additional mutations and ligands that stabilize intermediate conformational states are needed to fully understand the activation mechanism. These and other key issues in the field are collected in the Outstanding Questions. Our analysis shows that the ARs constitute a family of GPCRs with an exceptional knowledge base of structural, biochemical and pharmacological data, which configures a useful and dynamic map to design orthosteric and allosteric modulators, and envisage molecular switches involved in receptor activation and signaling.
Box 1: Experimental and computational methods to investigate binding and signaling events in

ARs.
Site-directed mutagenesis: A classical molecular biology method, where a single mutation is engineered in the DNA sequence codifying the receptor, to further investigate receptor structural or biological properties. Ligand binding affinities are measured in terms of their ability to competitively displace the radioligand, yielding ligand affinity ratios between the receptor mutant and wild-type (wt) variants. An analogous comparison can be made in functional assays to evaluate the effect on the potency or efficacy of agonists.
Neoceptor: An approach to investigate the (direct) role of residues in ligand binding, where the (fractional) charges of both ligand and protein are simultaneously reversed to investigate the (direct) role of residues in ligand binding. It was first introduced by Jacobson et al. into the AR field and has since been used in several examples [40, 41] .
Thermostabilization: A mutagenesis strategy to increase the thermostability of GPCRs, leading to the so-called Stabilized Receptors (StaRs). This method has been patented and applied on the A2AAR, resulting in A2A-StaR2 that contained 8 mutations, which stabilized the antagonist state of the receptor: A54L 2x52 (A/A/A/A), T88A 3x36 (T/T/T/T), data for a set of ligands versus each active site mutation is then generated, providing specific affinity and kinetic information (Kd, kon, and koff) of receptor-ligand interactions. This proprietary method has been used in the discovery of A2AAR antagonists [11, 22] . NMR: Classical NMR experiments recently revealed the conformational selection of ligands for certain receptor states [20] , while the NMR determination of interligand NOEs for pharmacophore mapping (INPHARMA) was employed to obtain information on ligand poses inside the binding site of the A2AAR reconstituted into nanodiscs [52] In silico site-directed mutagenesis. This protocol, based on free energy perturbation of residue sidechains, can be used to identify the molecular interactions that are gained or lost as a result of the point mutation. Since the corresponding shifts in ligand binding free energy are related to molecular interactions, as demonstrated on 34 of the A2AAR mutants described in this review [24, 26] . are exceptions bearing structurally simple, monocyclic cores. Other antagonists have been described for ARs, but we here focus on those for which there is mutational and structural data.
Box 3: Generic residue numbering
All residues and their mutations have been numbered according to the following scheme:
A000B Tx00 (C/D/E/F) Where: A = the wild-type residue. 000 = the residue number of the mutated residue, this number corresponds with the residue numbering of the receptor under investigation. B = the mutated residue, if no mutation is given this entry is left blank. Tx00 = the GPCRdb numbering scheme, which is a structure-based update of the Ballesteros-Weinstein (B-W) numbering scheme. T represents the transmembrane helix number and 00 the correlative residue number. The latter starts at the most conserved topological position in each helix, which is numbered 50. Here we adopt the last modifications to this numbering scheme, accounting for structural kinks and bulges in the alignment and numbering [81] . Residues in an inter-or extracellular domain of the receptor are represented using 00x00 , where the first two numbers depict the two transmembrane domains before and after the inter-or extracellular domain. If the residue position is not conserved, which is mostly the case in extra and intracellular loops and termini, no number is assigned and instead it is indicated the loop region where it belongs (EL1-IL3). C/D/E/F = the residue type in adenosine A1, A2A, A2B and A3 respectively, which will be given once in a paragraph. 23 The topological domains were classified as TM1-7 for the seven transmembrane helices, H8 (the C-terminal α helix), EL1-3 for the extracellular and IL1-3 to the intracellular loops. Na + as revealed in the A2AAR inactive structure (orange, hydrogen bonds in dashed lines). In agonistbound structures, this pocket is collapsed because of a bulge in TM7 around residue N284 7.49 , which is incompatible with the binding of Na + , explaining the mechanism of sodium as NAM. This also applies for the fully-active, G-Protein mimic bound A2AAR structure (green). The table shows the effect of selected alanine mutations of the A2AAR on binding (and potency) of the different pharmacological classes of orthosteric ligands. A detrimental effect is shown in red, while blue denotes an increasing effect. In both cases a high intensity of such effect (>30 fold) is depicted by a darker color. a There is only thermostability data available for F2426x44. b No measurable activation by agonists due to high basal activities. NE = no effect. 
Outstanding Questions Box
Ligand selectivity between receptor subtypes can be achieved by exploiting sequence differences within the binding site (selectivity hotspots), but it also can be due to residues in the loop regions distal from the binding site. Additionally, the latest crystal structures revealed large conformational differences in both regions between adenosine receptors. To what extend do these structural properties contribute to ligand selectivity?
The stereospecific ribose moiety is a characteristic feature of full agonists, while partial agonists have a mimic that is predicted to sit in the same binding site. Why do the same mutations in the ribose pocket have a different effect on full and partial agonists? Do these different classes of agonists maybe stabilize different intermediate receptor states?
The activation pathway in class-A GPCRs seems to be quite conserved. Still, adenosine receptors present specific structural signatures related to agonist specific interactions and receptor activation: Is the TDY-triad a regulatory motif in the activation of adenosine receptors? How does the ribose trigger receptor activation?
The residence time for a ligand can be quite different between receptor subtypes, and the mutagenesis and structural data suggest that ligand binding kinetics is controlled to a big extent by the extracellular loop region. What are the structural and dynamic determinants behind this control mechanism?
There is direct structural evidence for a sodium binding site for allosteric modulation, and indirect (mutagenesis) evidence for a second site in the EL region. Will future crystal structures confirm the existence of this allosteric site?
Can allosteric ligands modulate loop dynamics, thus affecting the residence time
